Chemical Compound Review:
CHEMBL85606 N-[4-[2-(6-cyano-3,4-dihydro- 1H...
Synonyms:
cc-478, SureCN3099712, SureCN3099718, CS-0368, HY-10847, ...
- SB-277011 GlaxoSmithKline. Remington, G., Kapur, S. Current opinion in investigational drugs (London, England : 2000) (2001)
- Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Gyertyán, I., Sághy, K. Behavioural pharmacology. (2004)
- Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. Stemp, G., Ashmeade, T., Branch, C.L., Hadley, M.S., Hunter, A.J., Johnson, C.N., Nash, D.J., Thewlis, K.M., Vong, A.K., Austin, N.E., Jeffrey, P., Avenell, K.Y., Boyfield, I., Hagan, J.J., Middlemiss, D.N., Reavill, C., Riley, G.J., Routledge, C., Wood, M. J. Med. Chem. (2000)
- Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Austin, N.E., Baldwin, S.J., Cutler, L., Deeks, N., Kelly, P.J., Nash, M., Shardlow, C.E., Stemp, G., Thewlis, K., Ayrton, A., Jeffrey, P. Xenobiotica (2001)